Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma

Lucas, Minke W., Versluis, Judith M., Rozeman, Elisa A., Blank, Christian U. · 2023 · Nature Reviews Clinical Oncology

Abstract

Neoadjuvant immune-checkpoint inhibition is a promising emerging treatment approach for patients with surgically resectable macroscopic stage III melanoma. The neoadjuvant setting provides an ideal platform for personalized therapy owing to the very homogeneous nature of the patient population and the opportunity for pathological response assessments within several weeks of starting treatment, thereby facilitating the efficient identification of novel biomarkers. A pathological response to immune-checkpoint inhibitors has been shown to be a strong surrogate marker of both recurrence-free survival and overall survival, enabling timely analyses of the efficacy of novel therapies in patients with early stage disease. Patients with a major pathological response (defined as the presence of ≤10% viable tumour cells) have a very low risk of recurrence, which offers an opportunity to adjust the extent of surgery and any subsequent adjuvant therapy and follow-up monitoring. Conversely, patients who have only a partial pathological response or who do not respond to neoadjuvant therapy still might benefit from therapy escalation and/or class switch during adjuvant therapy. In this Review, we outline the concept of a fully personalized neoadjuvant treatment approach exemplified by the current developments in neoadjuvant therapy for patients with resectable melanoma, which could provide a template for the development of similar approaches for patients with other immune-responsive cancers…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00760-3

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 132 references

Research works printed but not linked: 3

  1. Tarhini, A. et al. Neoadjuvant intratumoral TAVO-EP (plasmid IL- 12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma [abstract 617]. J. Immunother. Cancer 10 (Suppl. 2), A649 (2022).
  2. Reschke, R., Jager, I., Mehnert-Theuerkauf, A. & Ziemer, M. Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies. J. Dtsch. Dermatol. Ges. 19, 215–221 (2021).
  3. Davar D, K. A. et al. Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): preliminary results. Presente. SITC 2019, 6–10 (2019).

Cited by

See all 51

Metadata

Authors
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U.
Affiliations
  • The Netherlands Cancer Institute (NL)
  • Leiden University Medical Center (NL)
Corresponding author
Blank, Christian U.
Venue
Nature Reviews Clinical Oncology
Published
2023-05-05
Volume
20
Issue
6
Pages
408-422
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4372185169
Cited by
50
References
132
Citations by year
2026: 9 · 2025: 14 · 2024: 24 · 2023: 3
FWCI
1.62
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
melanoma, stage III melanoma, pathological response, biomarkers, personalized treatment, treatment escalation, adjuvant therapy, recurrence-free survival, overall survival
MeSH terms
Immune Checkpoint Inhibitors, Combined Modality Therapy, Humans, Melanoma, Skin Neoplasms, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. https://app.cochat.ai/papers/10.1038/s41571-023-00760-3
The paper
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023). Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00760-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.